Prevalence of abnormal hematocrit values (HCT) in diabetic is a phenomenon that is underestimated by physicians and diabetes nurse educators. HCT is generally considered to be quite stable in the range of 40-45% and blood glucose meters for patient self-testing are usually set to function properly with HCT concentration in this "normal range." However, a thorough investigation of the hematocrit distribution in an urban community has demonstrated a HCT-range of 30-50% in a healthy reference population. In community patients, the observed HCT ranged between 20% and 60%, and in hospital patients it was 10% to 70%. Patients in the intensive care units showed levels between 15% and 40%.
lower than normal hematocrit values (<35%) can result in overestimating readings in comparison to the laboratory glucose levels, whereas hematocrit values higher than normal (>45%) may result in underestimates of laboratory values. [8] [9] [10] [11] [12] [13] The primary reason for this issue is the internal calibration of the analysis process, which is based on the assumption of a standardized 45% hematocrit value of the sample. Among the various hypotheses that have been suggested to explain the impact of abnormal hematocrit levels on glucose testing are alterations in the viscosity of the blood, a possible blocking of the plasma glucose to reaching the reaction surface of the test strip, changes in diffusion kinetics, and/or increased packed red cell volume and displacement of plasma volume leading to insufficient plasma volume for accurate testing at the electrode. 14 Possible technology solutions to avoid hematocrit interference include the parallel measurement of hematocrit with a subsequent correction algorithm as employed by the pointof-care StatStrip device (NovaBiomedical, Waltham, MA). 15, 16 An alternative approach to reduce hematocrit interference is the application of a physical and mathematical result correction also referred to "dynamic electrochemistry." We have been able to demonstrate in recent investigations that devices for patient self-testing employing dynamic electrochemistry are unaffected not only by hematocrit interference in the laboratory [17] [18] [19] but also in a clinical accuracy evaluation. 20 A new device employing dynamic electrochemistry, MyStar Extra (Sanofi, Frankfurt), has recently been introduced to the market. The purpose of this investigation was to confirm that the dynamic electrochemistry algorithms established in the MyStar Extra device are suitable to correct for hematocrit interference by using our standardized hematocrit interference testing protocol in comparison to 7 commercially available competitive devices.
Materials and Methods

Study Devices
The study devices with 1 exception and all strips were purchased by us from regular pharmacy supplies. The study device MyStar Extra was provided by Sanofi. In addition, the following glucose meters were included in this study: Contour XT, Contour Link (Bayer, Leverkusen, Germany), FreeStyle Lite (Abbott, Wiesbaden, Germany), My Life Pura (Ypsomed, Bad Schwalbach, Germany), Accu-Chek Aviva Nano, Accu-Chek Performa (Roche Diagnostics, Mannheim, Germany), and OneTouch Verio Pro (LifeScan, Neckargemünd, Germany). The YSI (Yellow Springs Instrument) 2300 STAT PLUS Glucose Analyzer (Life Sciences, GOD method, Langenfeld, Germany) was utilized as reference method. All devices and supplies were stored and operated in accordance with manufacturer's instructions.
Collection of Blood Samples and Laboratory Settings
Sample preparation and processing was performed by a standardized protocol as published previously. 17 Blood samples were collected in compliance with local ethical and legal requirements. Venous, heparinized whole blood was drawn on the day of the experiment and immediately manipulated to contain 3 different blood glucose concentrations and 5 different hematocrit levels (15 different samples in total). Samples were aliquoted and stored at 4°C until measurement. Before the start of the experiment, glucose concentration, hematocrit values, and the degree of oxygen saturation were confirmed by means of the ABL80 FLEX CO-OX blood gas analyzer (Drott, Wiener Neudorf, Austria) and carefully adjusted if necessary. The degree of oxygenation had to remain within physiological capillary values (range, 80-100%). Prior to start the measurements, all glucose meters were checked for proper function with quality control solutions. Glucose measurements were conducted using 2 devices of each meter type and 2 test strip lots. Each meter/strip combination was tested 8 times (8 measurements/meter/test strip lot/sample = 480 measurements in total). All tests were carried out simultaneously for each meter by a group of trained personnel in a laboratory setting with controlled room temperature (21 ± 4°C) and humidity (44-68%).
Sample Processing
The freshly drawn blood was spiked to 3 target glucose concentrations using a 10% concentrated glucose solution (Serag-Wiessner KG, Naila, Germany) to the following target ranges: 50-80 mg/dL, 150-180 mg/dL, and 350-400 mg/dL. The blood was gently mixed in a 15 mL test tube and aliquted. Subsequently, part of the samples were carefully centrifuged to separate cells from plasma and both fractions were used to adjust other aliquots to a desired hematocrit target level (approx. 20-25%, 30-35%, 40-45%, 50-55%, and 60-65%). The hematocrit and the oxygen pressure were verified in each manipulated sample by means of ABL80 FLEX CO-OX blood gas analyzer (Sendx Medical/Radiometer, Carlsbad, CA). If the oxygenation saturation was below the meter specifications (ie, out of physiological range), individual samples were carefully oxygenized by gently inverting the tube at room temperature. Following repeated hematocrit and oxygen saturation measurements and confirmation of readjusted values, an aliquot of the individual sample was centrifuged at 300 × g for 5 minutes at 4°C to separate plasma from red blood cells. The obtained plasma was measured with the reference device at room temperature.
Statistical Analyses
The data were collected and tabulated for each meter. Statistical analyses included calculation of the mean values and standard deviations for each meter type/sample combination. The mean of the differences from the comparison method was used for calculating the mean absolute relative deviation (MARD) for each meter at the 3 glucose concentrations. This accuracy analysis as well as the determination of the coefficient of variation (precision) was performed only with the samples that showed a hematocrit value of 45%. The mean glucose value determined at a hematocrit of 45% was normalized to be 100% to determine the potential bias (% deviation) occurring at the other hematocrit levels. The means of the deviations between the different hematocrit samples were used for calculating a hematocrit interference factor (HIF = largest observed bias above 100% + largest observed bias below 100%) for each meter with the mean relative results obtained from the 3 glucose concentrations. An HIF < 15% for the individual glucose level and a mean HIF over the entire glucose ranges < 10% was predefined as indicative for no clinically relevant influence of hematocrit on the blood glucose readings, as defined previously. 17 Comparisons between mean values were calculated by means of the 2-sided Student's t test. A P value < .05 was considered statistically significant.
Results
All glucose measurements for each individual blood sample were completed by all meters within 13 minutes after the release of the sample for study measurements. In total, 480 measurements were performed on 15 manipulated blood samples per BGM type using 2 devices and 2 glucose strip lots (except for Accu-Chek Performa for which only 1 test strip lot was available on the market). The achieved final blood glucose values, as determined by the YSI plasma reference device, were within 58-67 mg/dL, 156-159 mg/dL, and 368-371 mg/dL. The hematocrit values were confirmed to be within 24.6-25.2%, 30.3-33.0%, 42.1-43.6%, 50.2-53.2%, and 60.1-62.5%, respectively. Figure 1 illustrates the performance of the MyStar Extra device at the different hematocrit levels over 3 glucose concentrations. As can be seen, the device technology was confirmed to be stable against hematocrit interference. The results of the other devices tested are shown in Figures 2 and 3 . Like in previous similar investigations, the 2 Accu-Chek devices showed hematocrit sensitivity, as does MyLife Pura and FreeStyle Lite. No or only minor interference was determined for OneTouch Verio Pro, Contour XT, and Contour Link.
Considering an HIF < 15% for the individual glucose levels and an HIF < 10% over the entire glucose range arbitrarily to be the criteria for "noninterference" for clinical use, 17 only 4 out of 8 tested devices would have met the stringent requirements: Contour XT (6%), MyStar Extra (7%), OneTouch Verio Pro (7%), and Contour Link (9%; see Figure 4 ).
The accuracy of MyStar Extra versus the comparator devices is shown in Table 1 . The closest overall accuracy results in this experiment were recorded for Contour XT device (MARD: 1.6%). All 8 tested devices exhibited very good precision results not exceeding 15%. The lowest overall precision results were obtained by the OneTouch Verio Pro device (4.0%).
Discussion
Dynamic electrochemistry is a well known physicochemical method and was originally used to measure 2 different chemical substances in 1 aqueous solution. It has been further developed for use in more complex sample matrices and was finally incorporated into commercially available blood glucose meters for patient self-measurement, such as the BG*Star and iBG*Star devices from Sanofi-Aventis, 21 and recently in the new device MyStar Extra. The mathematical model is based on the assumption that each oxidation process leads to an electrode signal, which can be represented by a unique vector based on a phase angle (psi) and a unique vector length (YO) in a 3-dimensional space. The concentration of each substance in the sample leading to an electron transfer can be determined by monitoring the change in the admittance magnitude in the direction of the characteristic angle for that particular substance when applying different baseline measurement conditions (frequency, voltage, etc). The total Faradaic admittance for all electro-active substances present is given by a linear combination of the independent vectors from the different species. By performing measurements at different measurement conditions, it is possible to calculate the individual contribution of an interfering substance based on the knowledge of the substance-specific phase angle of the oxidation signal. Existing calibration curves and the knowledge about phase angle and vectors are the basis to measure glucose in samples containing several electro-active substances by correcting the measured total admittance from several underlying measurement conditions for the influence of a variety of known interfering conditions and substances. 21, 22 In our laboratory study with MyStar Extra, the application of this method lead to accurate readings independent from hematocrit variation. As to be expected, the results are similar to those obtained with other blood glucose meters employing dynamic electrochemistry in a previous investigation. 18 Next to the sponsor device, 3 other meters were also demonstrating stability to hematocrit interference. The same meters or meters from the same manufacturers and based on the respective technology have also shown similar results in previous investigations. [17] [18] [19] [20] These blood glucose measurement systems are also known to use mathematical algorithms to correct for hematocrit interference, but the exact nature of these procedures has not been disclosed to the public, but it is tempting to speculate that it may be a similar approach like dynamic electrochemistry. The meters that failed our hematocrit interference test are known to apply static electrochemistry, which explains the observed results.
The acceptance criteria of an HIF of 10% has been arbitrarily selected based on current laboratory standards for general substance interference testing with biochemical methods and is also based on clinical considerations, for example, the likelihood of choosing a different insulin dose if a value is too high or too low due to hematocrit interference. This threshold has been applied by us in previous publications and appears to be a suitable benchmark parameter to differentiate between devices with or without hematocrit interference. [17] [18] [19] [20] Our investigation has several important limitations, which prohibit a direct translation of our laboratory results into clinical practice recommendations. First, this investigation was performed in an artificial laboratory setting with manipulated venous samples. While we have been able to develop a very robust protocol leading to good accuracy results, this study was designed to provide information regarding the effect of hematocrit on the underlying technology of the investigated meters. However, all explored devices are designed to optimally operate in accordance with the instructions for use, that is, with capillary blood obtained from the fingertip in a clinical environment. Therefore, we have not interpreted the obtained data about the observed absolute accuracy or precision.
Second, sample specimen and environmental factors were controlled in our experiment for all devices; other factors such as the complexity of chemical reactions, the involvement of different coenzymes, and additional unknown strip components may have further influenced our results. In this context, it is important to mention that oxygen pressure plays Hematocrit interference factor of all tested devices for benchmark comparison of hematocrit interference. 17 strips based on a glucosede-hydrogenase method. However, while all meters are calibrated against glucoseoxidase reference methods, the 2 Accu-Chek devices are calibrated with a glucohexokinase technology. Only MyStar Extra and MyLife Pura operate with glucose-oxidase based strips and are calibrated with glucose-oxidase based methods. In our study, we used the glucose oxidase-based YSI analyzer as the comparison method. This experimental design may have influenced the reported accuracy results. A negative bias of 3-8% has been described between YSI 2300 STAT and the hexokinase-based Olympus AU640 reference method. 23, 24 As such, different reference methods might introduce a deviation of the values, which is not caused by the device itself. While we believe that these limitations do not change the meaning of our hematocrit interference findings, they have to be considered when interpreting our data.
In conclusion of this study, all meters showed a good accuracy in a laboratory setting, but only 50% of them, including MyStar Extra, were shown to reliably correct for potential hematocrit influence on the meter results. The limitations of our laboratory approach have to be taken into account when drawing conclusions for the clinical patient care.
